{"name":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","slug":"han-xu-m-d-ph-d-fapcr-sponsor-investigator-irb-chair","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Abiraterone - Usual","genericName":"Abiraterone - Usual","slug":"abiraterone-usual","indication":"Metastatic castration-resistant prostate cancer","status":"phase_2"},{"name":"ETOPOSIDE - Usual","genericName":"ETOPOSIDE - Usual","slug":"etoposide-usual","indication":"Acute lymphoblastic leukemia","status":"phase_2"},{"name":"Alectinib - Usual","genericName":"Alectinib - Usual","slug":"alectinib-usual","indication":"Metastatic non-small cell lung cancer with ALK rearrangement","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Alectinib - Study","genericName":"Alectinib - Study","slug":"alectinib-study","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Abiraterone - Usual","genericName":"Abiraterone - Usual","slug":"abiraterone-usual","phase":"phase_2","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that blocks the production of testosterone in the body.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"ETOPOSIDE - Usual","genericName":"ETOPOSIDE - Usual","slug":"etoposide-usual","phase":"phase_2","mechanism":"Etoposide is a topoisomerase II inhibitor that works by interfering with the enzyme topoisomerase II, which is involved in DNA replication and cell division.","indications":["Acute lymphoblastic leukemia","Small cell lung cancer","Testicular cancer","Hodgkin's lymphoma","Non-Hodgkin's lymphoma"],"catalyst":""},{"name":"Alectinib - Study","genericName":"Alectinib - Study","slug":"alectinib-study","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alectinib - Usual","genericName":"Alectinib - Usual","slug":"alectinib-usual","phase":"phase_2","mechanism":"Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein.","indications":["Metastatic non-small cell lung cancer with ALK rearrangement","Locally advanced or metastatic non-small cell lung cancer with ALK rearrangement"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":4},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}